RecruitingPhase 1NCT06721299

Clenbuterol to Target DUX4 in FSHD

Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol

Sponsor

Jeffrey Statland

Enrollment

30 participants

Start Date

Jun 25, 2025

Study Type

INTERVENTIONAL

Conditions

Muscular Dystrophy, Facioscapulohumeral

Summary

The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Clenbuterol for people with muscular dystrophy, facioscapulohumeral. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGClenbuterol

Beta-Agonist

Locations(3)

University of Kansas Medical Center

Kansas City, Kansas, United States

University of Rochester Medical Center

Rochester, New York, United States

University of Washington

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06721299

Related Trials

Disease Burden and Living Situation of Patients With Facioscapulohumeral Muscular Dystrophy

NCT065174981 location